A Double-Blind, Placebo-Controlled, Phase 2, Responsive Adaptive Randomization Study of ORP-101 in Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2019
Price : $35 *
At a glance
- Drugs ORP 101 (Primary)
- Indications Diarrhoea; Irritable bowel syndrome; Pain
- Focus Proof of concept; Therapeutic Use
- Sponsors OrphoMed
- 05 Dec 2019 Status changed from not yet recruiting to recruiting.
- 15 Oct 2019 Status changed from planning to not yet recruiting.
- 30 Apr 2018 New trial record